[Hormone replacement therapy in @entity0 XXXX : a study of 230 @entity1 , with a case-control study].

@entity1 @entity0 @entity5 @entity53 @entity1871 @entity65 @entity3 @entity546 @entity1558 @entity34
OBJECTIVES: After recalling the classical contra-indication of @entity34 ( @entity34 ) concerning @entity1 with a personal history of @entity0 ( @entity0 ), and arguments that may be opposed, the authors report the present results of a prospective study undertaken in the Center of @entity1558 in Saint-Louis hospital in Paris since February 1992. @entity1 AND METHODS: By April 2001, 230 @entity1 had been included. A free interval of 2 years at least since the treatment of the primary @entity0 has been observed. The reasons for prescribing @entity34 were vasomotor troubles (flushes, nightly sweats) or a @entity546 , which were severe and not controlled by non-hormonal treatments. There was also an indication of a major @entity65 . In fact, many of these @entity1 had a premature, artificial, chemo-induced menopause. The @entity34 most often used was an estro-progestin association ( @entity53 + a @entity1871 compound) given either continuously or with a 5-d interruption each month. The mean duration of treatment was 2.5 years. RESULTS: Results, concerning the improvement of menopause troubles, were remarkable in the great majority of troubles. @entity34 had to be stopped in 39 cases, reading as follows: 17 cases for relapses (seven local, six in the contro-lateral breast and four @entity3 (7%)). Also, 22 @entity1 (9%) interrupted their @entity34 for serious side-effects. A case-control study did not show any significant difference between with and without @entity34 @entity1 concerning the overall survival without relapse. DISCUSSION AND CONCLUSIONS: Quality of life of @entity1 was often substantially improved, and a deleterious effect on the @entity5 was not found. Our results are in agreement with the literature from other countries. However, one must be cautious. In such circumstances, @entity34 must be prescribed with the informed consent of the @entity1 and delivered in appropriate hospital and university centers. It is wished that large randomised prospective studies may be undertaken.
